Status:
COMPLETED
Preventive Effects of Cetylpyridinium Chloride on SarcopeniaStudy
Lead Sponsor:
Seoul National University Hospital
Conditions:
Sarcopenia
Eligibility:
All Genders
60+ years
Phase:
EARLY_PHASE1
Brief Summary
This study is to assess the impact on the prevention of sarcopenia after taking cetylpyridinium chloride targeting the patients of presarcopenia over the age of 60.
Detailed Description
65 people that meet the inclusion criteria on screening test are assigned to one of five groups by randomization. They take the medication for two weeks under double-blind. Four study groups take cety...
Eligibility Criteria
Inclusion
- Presarcopenia A. Reduced skeletal muscle mass (ASM/height2) M \< 7.0kg/m2, F \< 5.7kg/m2 B. Normal grip strength M ≥ 26kg, F ≥ 18kg C. Normal physical performance Gait speed \> 0.8m/s
- Community dwelling
Exclusion
- History of stroke or spinal cord injury
- Artificial joint
- Acute disease or unstable chronic disease
- Phenylketonuria
- History of myocardiac infarction
- Allergic contact dermatitis
- History of drug/alcohol addiction, habitual smoker
Key Trial Info
Start Date :
November 13 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2015
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT02297997
Start Date
November 13 2014
End Date
November 1 2015
Last Update
March 29 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.